Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Olanzapine (Excl. Dafo. For The Production Of A Depot - Isu, Atc N05Ah03 (Obo) For The Period 01.08.24 - 31.07.26

  Address - Germany

  Contact details - 565656565

  Tender notice no. - 76454545

  GT Ref Id - 83248232

  Document Type - Tender Notices

Description - Description: Section 130a paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for medicines dispensed at the expense of statutory health insurance companies. In view of the relev ant statutory provisions for the award of public contracts, DAK-Gesundheit carries out a regular process of active ingredient-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For medicines containing the above-mentioned active ingredient, olanzapine (only dosage forms for the manufacture of a depot injection suspension), ATC N05AH03, which are to be named by the bidder in Annex 2 to the contract, DAK-G

Gt Ref Id - 83248232

Deadline - Jun 05, 2026